Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is a prevalent cancer, often diagnosed at a metastatic stage.
• Pemetrexed is a key chemotherapy agent for NSCLC, targeting folate-dependent enzymes like thymidylate synthase (TS).
• Elevated TS expression is linked to pemetrexed resistance and poorer patient outcomes.

Purpose of the Study:

• To investigate the synergistic effects of combining rapamycin, an mTOR inhibitor, with pemetrexed in NSCLC.
• To determine the impact of this combination on TS expression and NSCLC cell proliferation.

Main Methods:

• In vitro studies using NSCLC cell lines.
• In vivo studies involving NSCLC xenografts in animal models.
• Assays to measure mTOR activity and TS expression levels.

Main Results:

• The combination of rapamycin and pemetrexed demonstrated synergistic inhibition of NSCLC cell proliferation in vitro.
• Rapamycin pretreatment suppressed pemetrexed-induced TS expression.
• In vivo, the combination therapy significantly inhibited NSCLC xenograft growth, associated with reduced mTOR activity and TS expression.

Conclusions:

• Rapamycin enhances the efficacy of pemetrexed in NSCLC by suppressing TS induction.
• The combination therapy shows promise for NSCLC treatment, warranting further clinical investigation.
• Findings support the development of clinical trials combining mTOR inhibitors with pemetrexed for NSCLC patients.